These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25170637)

  • 1. ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme.
    Marchetti A; Barberis M; Papotti M; Rossi G; Franco R; Malatesta S; Buttitta F; Ardizzoni A; Crinò L; Gridelli C; Taddei GL; Clemente C; Scagliotti G; Normanno N; Pinto C
    J Thorac Oncol; 2014 Oct; 9(10):1470-6. PubMed ID: 25170637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of the First Italian External Quality Assurance Scheme for somatic EGFR mutation testing in non-small-cell lung cancer.
    Normanno N; Pinto C; Taddei G; Gambacorta M; Castiglione F; Barberis M; Clemente C; Marchetti A
    J Thorac Oncol; 2013 Jun; 8(6):773-8. PubMed ID: 23575414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.
    V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M
    Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter ALK testing in non-small-cell lung cancer: results of a round robin test.
    von Laffert M; Penzel R; Schirmacher P; Warth A; Lenze D; Hummel M; Dietel M
    J Thorac Oncol; 2014 Oct; 9(10):1464-9. PubMed ID: 25170635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria.
    von Laffert M; Warth A; Penzel R; Schirmacher P; Kerr KM; Elmberger G; Schildhaus HU; Büttner R; Lopez-Rios F; Reu S; Kirchner T; Pauwels P; Specht K; Drecoll E; Höfler H; Aust D; Baretton G; Bubendorf L; Stallmann S; Fisseler-Eckhoff A; Soltermann A; Tischler V; Moch H; Penault-Llorca F; Hager H; Schäper F; Lenze D; Hummel M; Dietel M
    J Thorac Oncol; 2014 Nov; 9(11):1685-92. PubMed ID: 25436802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization.
    Tembuyser L; Tack V; Zwaenepoel K; Pauwels P; Miller K; Bubendorf L; Kerr K; Schuuring E; Thunnissen E; Dequeker EM
    PLoS One; 2014; 9(11):e112159. PubMed ID: 25386659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
    Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
    J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
    Kim H; Yoo SB; Choe JY; Paik JH; Xu X; Nitta H; Zhang W; Grogan TM; Lee CT; Jheon S; Chung JH
    J Thorac Oncol; 2011 Aug; 6(8):1359-66. PubMed ID: 21587085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients.
    Vidal J; Clavé S; de Muga S; González I; Pijuan L; Gimeno J; Remón J; Reguart N; Viñolas N; Gironés R; Bernet L; Majem M; Bosch-Barrera J; Porta R; Alonso N; Palmero R; Taus A; Albanell J; Espinet B; Salido M; Arriola E
    J Thorac Oncol; 2014 Dec; 9(12):1816-20. PubMed ID: 25393795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH.
    Hutarew G; Hauser-Kronberger C; Strasser F; Llenos IC; Dietze O
    Histopathology; 2014 Sep; 65(3):398-407. PubMed ID: 24612196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing ALK Immunohistochemistry and In Situ Hybridization Proficiency Testing for Non-Small Cell Lung Cancer in Canada: Canadian Immunohistochemistry Quality Control Challenges and Successes.
    Cheung CC; Garratt J; Won J; Cutz JC; Gilks BC; Tsao M; Torlakovic EE
    Appl Immunohistochem Mol Morphol; 2015; 23(10):677-81. PubMed ID: 26551338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.
    Tan CL; Lim TH; Lim TKh; Tan DS; Chua YW; Ang MK; Pang B; Lim CT; Takano A; Lim AS; Leong MC; Lim WT
    Oncotarget; 2016 Apr; 7(17):23251-62. PubMed ID: 26993609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
    Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA
    J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.
    Conklin CM; Craddock KJ; Have C; Laskin J; Couture C; Ionescu DN
    J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23196275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
    Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
    Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology.
    Marchetti A; Ardizzoni A; Papotti M; Crinò L; Rossi G; Gridelli C; Barberis M; Maiorano E; Normanno N; Taddei GL; Scagliotti G; Clemente C; Pinto C
    J Thorac Oncol; 2013 Mar; 8(3):352-8. PubMed ID: 23407559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.
    Jiang L; Yang H; He P; Liang W; Zhang J; Li J; Liu Y; He J
    Am J Surg Pathol; 2016 May; 40(5):697-703. PubMed ID: 26825369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
    Pailler E; Adam J; Barthélémy A; Oulhen M; Auger N; Valent A; Borget I; Planchard D; Taylor M; André F; Soria JC; Vielh P; Besse B; Farace F
    J Clin Oncol; 2013 Jun; 31(18):2273-81. PubMed ID: 23669222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material.
    Minca EC; Lanigan CP; Reynolds JP; Wang Z; Ma PC; Cicenia J; Almeida FA; Pennell NA; Tubbs RR
    J Thorac Oncol; 2014 Apr; 9(4):464-8. PubMed ID: 24736067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment of ALK rearrangement in non-small cell lung cancer: using enhancing immunohistochemical way and fluorescence in situ hybridization].
    Meng H; Gao X; Zhang L; Liu F; Li W
    Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):75-9. PubMed ID: 25676399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.